$4.40
1.50% today
Nasdaq, Jul 17, 03:52 pm CET
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Sana Biotechnology Inc Stock price

$4.33
+1.81 71.83% 1M
+1.08 33.23% 6M
+2.70 165.64% YTD
-2.53 36.88% 1Y
-3.14 42.03% 3Y
-30.77 87.66% 5Y
-30.77 87.66% 10Y
-30.77 87.66% 20Y
Nasdaq, Closing price Wed, Jul 16 2025
+0.15 3.59%
ISIN
US7995661045
Symbol
SANA
Sector
Industry

Key metrics

Basic
Market capitalization
$976.7m
Enterprise Value
$872.0m
Net debt
positive
Cash
$104.7m
Shares outstanding
225.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.7
Financial Health
Equity Ratio
50.0%
Return on Equity
-106.5%
ROCE
-51.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-195.3m | $-194.8m
EBIT
$-212.6m | $-220.4m
Net Income
$-208.7m | $-176.2m
Free Cash Flow
$-223.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
34.0% | 23.7%
EBIT
33.5% | 19.2%
Net Income
32.4% | 33.9%
Free Cash Flow
18.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.9
FCF per Share
$-1.0
Short interest
76.6%
Employees
328
Rev per Employee
$0.0
Show more

Is Sana Biotechnology Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,998 stocks worldwide.

Sana Biotechnology Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a Sana Biotechnology Inc forecast:

12x Buy
86%
2x Hold
14%

Analyst Opinions

14 Analysts have issued a Sana Biotechnology Inc forecast:

Buy
86%
Hold
14%

Financial data from Sana Biotechnology Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 59 59
19% 19%
-
- Research and Development Expense 198 198
23% 23%
-
-195 -195
34% 34%
-
- Depreciation and Amortization 17 17
28% 28%
-
EBIT (Operating Income) EBIT -213 -213
34% 34%
-
Net Profit -209 -209
32% 32%
-

In millions USD.

Don't miss a Thing! We will send you all news about Sana Biotechnology Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Sana Biotechnology Inc Stock News

Neutral
GlobeNewsWire
24 days ago
Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression
Neutral
GlobeNewsWire
about one month ago
Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes Presentation to highlight updated six-month clinical results of a hypoimmune-modified primary pancreatic islet cell therapy for patients with type 1 diabetes
Neutral
GlobeNewsWire
about 2 months ago
SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update.
More Sana Biotechnology Inc News

Company Profile

Sana Biotechnology, Inc. engages in the research and development of engineered cells as medicine. It focuses in identifying and developing potential product candidates, executing preclinical studies, and acquiring technology. The company was founded by Steven D. Harr, Noubar B. Afeyan, Robert Taylor Nelsen, and Hans Edgar Bishop on July 13, 2018 and is headquartered in Seattle, WA.

Head office United States
CEO Steven Harr
Employees 328
Founded 2018
Website sana.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today